We are live on ! Find out more
DCPH

Deciphera Pharmaceuticals, Inc. Common Stock
DCPH

Delisted

DCPH was delisted on the 10th of June, 2024.

Back to rankings

49 hedge funds and large institutions have $275M invested in Deciphera Pharmaceuticals, Inc. Common Stock in 2017 Q3 according to their latest regulatory filings, with 49 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
49
Holders Change
+49
Holders Change %
–
% of All Funds
1.22%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.05%
New
49
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
NLVP
New Leaf Venture Partners
New York
+$75.2M
2
Viking Global Investors
Viking Global Investors
Connecticut
+$45.6M
3
SHI
SV Health Investors
Massachusetts
+$31.4M
4
RG
Redmile Group
California
+$13.2M
5
Millennium Management
Millennium Management
New York
+$12.6M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
NLVP
1
New Leaf Venture Partners
New York
$77.9M +$75.2M +4,104,140 New
Viking Global Investors
2
Viking Global Investors
Connecticut
$47.3M +$45.6M +2,491,542 New
SHI
3
SV Health Investors
Massachusetts
$32.6M +$31.4M +1,716,303 New
Millennium Management
4
Millennium Management
New York
$13.1M +$12.6M +688,231 New
RG
5
Redmile Group
California
$12M +$13.2M +722,880 New
O
6
OrbiMed
New York
$7.49M +$7.22M +394,270 New
EA
7
Emerald Advisers
Pennsylvania
$6.66M +$6.43M +350,740 New
DM
8
Deerfield Management
New York
$6.17M +$5.95M +325,000 New
EMFAT
9
Emerald Mutual Fund Advisers Trust
Pennsylvania
$5.55M +$5.35M +292,147 New
Citadel Advisors
10
Citadel Advisors
Florida
$4.96M +$4.79M +261,436 New
Adage Capital Partners
11
Adage Capital Partners
Massachusetts
$4.75M +$4.58M +250,000 New
Franklin Resources
12
Franklin Resources
California
$4.75M +$4.58M +250,000 New
LCM
13
Laurion Capital Management
New York
$4.27M +$4.12M +225,000 New
OM
14
Opaleye Management
Massachusetts
$4.12M +$3.98M +217,000 New
ACH
15
ArrowMark Colorado Holdings
Colorado
$3.82M +$3.69M +201,285 New
Hudson Bay Capital Management
16
Hudson Bay Capital Management
Connecticut
$3.8M +$3.66M +200,000 New
Vanguard Group
17
Vanguard Group
Pennsylvania
$3.46M +$3.33M +182,000 New
Lord, Abbett & Co
18
Lord, Abbett & Co
New Jersey
$3.42M +$3.3M +180,000 New
MIM
19
Monashee Investment Management
Massachusetts
$2.85M – – –
KCM
20
Kornitzer Capital Management
Kansas
$2.17M +$2.09M +114,350 New
Alyeska Investment Group
21
Alyeska Investment Group
Illinois
$1.97M +$1.9M +103,650 New
PA
22
Perceptive Advisors
New York
$1.95M +$1.88M +102,500 New
FCM
23
Farallon Capital Management
California
$1.9M +$1.83M +100,000 New
WMSA
24
Weiss Multi-Strategy Advisers
New York
$1.61M +$1.56M +85,000 New
Goldman Sachs
25
Goldman Sachs
New York
$1.42M +$1.37M +75,000 New
1
2

DCPH Hedge Fund Activity: Q3 2017 in Review

49 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) for Q3 2017, worth a combined $275M.

Buyers outnumbered sellers: 49 funds opened new DCPH positions and 0 closed out — a net gain of 49 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was New Leaf Venture Partners, opening a new position worth an estimated $75.2M.

  • 49 institutional investors held Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) as of Q3 2017, up from 0 in Q2 2017.
  • Funds reported $275M of Deciphera Pharmaceuticals, Inc. Common Stock stock for Q3 2017.
  • 49 funds opened new Deciphera Pharmaceuticals, Inc. Common Stock positions in Q3 2017 and 0 closed out, a net change of +49 holders.
  • The largest Deciphera Pharmaceuticals, Inc. Common Stock buyer in Q3 2017 was New Leaf Venture Partners, an estimated $75.2M added.

Based on aggregated 13F filings for Q3 2017.